Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Head and Neck Squamous Cell Carcinoma Clinical Trials

20 recruiting trials for Head and Neck Squamous Cell Carcinoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
20
Total Trials
20
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06238479

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The...

Sponsor: Eli Lilly and CompanyEnrolling: 49020 locations
RECRUITINGPhase 1 / Phase 2NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the...

Sponsor: Neonc Technologies, Inc.Enrolling: 1346 locations
RECRUITINGPhase 1NCT06451497

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With...

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have...

Sponsor: Zumutor Biologics Inc.Enrolling: 1003 locations
RECRUITINGPhase 1 / Phase 2NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or...

Sponsor: VM Oncology, LLCEnrolling: 24215 locations
RECRUITINGPhase 1NCT05005403

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and...

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer...

Sponsor: AbbVieEnrolling: 69420 locations
RECRUITINGPhase 1NCT03740256

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks...

Sponsor: Baylor College of MedicineEnrolling: 451 location
RECRUITINGPhase 1NCT05859074

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 567 locations
RECRUITINGPhase 1NCT07348211

First in Human Study of SIM0610 in Solid Tumors

This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of...

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.Enrolling: 2607 locations
RECRUITINGPhase 1NCT04119024

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic...

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of...

Sponsor: Anusha KalbasiEnrolling: 183 locations
RECRUITINGNCT06662058

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or...

This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in...

Sponsor: Emory UniversityEnrolling: 1181 location
RECRUITINGNCT04564989

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2)...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 2203 locations
RECRUITINGPhase 2NCT06855212

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

The purpose of the study is to determine if cemiplimab in combination with cetuximab given before their surgery are beneficial and safe in participants with head and neck squamous...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 211 location
RECRUITINGPhase 1NCT06806852

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps...

This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with...

Sponsor: Boehringer IngelheimEnrolling: 9020 locations
RECRUITINGPhase 2NCT04857164

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

This trial is main evaluate the efficacy and safety of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic head...

Sponsor: Yuankai ShiEnrolling: 1501 location
RECRUITINGNCT07511413

GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients

GALENOS 1 is a prospective observational study designed to explore longitudinal changes in nutritional status and body composition in patients with head and neck squamous cell...

Sponsor: Fondazione del Piemonte per l'OncologiaEnrolling: 1101 location
RECRUITINGPhase 2NCT06170710

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

This trial aims to evaluate whether the addition of anti-PD-1 antibody to adjuvant postoperative chemoradiotherapy could improve disease free survival in patients with high-risk...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 1731 location
RECRUITINGEarly Phase 1NCT06914999

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating...

This early phase I trial compares sodium fluoride F-18 (F-18 NaF) positron emission tomography (PET)/computed tomography (CT) to the standard of care imaging scan (and...

Sponsor: Emory UniversityEnrolling: 201 location
RECRUITINGEarly Phase 1NCT06700070

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in...

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of...

Sponsor: Pure Biologics S.A.Enrolling: 121 location
RECRUITINGPhase 1NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and...

Sponsor: KaliVir ImmunotherapeuticsEnrolling: 607 locations
RECRUITINGPhase 1NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced...

Sponsor: Nurix Therapeutics, Inc.Enrolling: 34517 locations

Frequently Asked Questions

There are currently 20 clinical trials for Head and Neck Squamous Cell Carcinoma, with 20 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Head and Neck Squamous Cell Carcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Head and Neck Squamous Cell Carcinoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.